Lineage Cell Therapeutics (LCTX) Invested Capital (2010 - 2026)

Lineage Cell Therapeutics has reported Invested Capital for 17 years, with the latest figure at $53.9 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 30.62% year-over-year to $53.9 million; the trailing twelve-month figure through Mar 2026 stood at $53.9 million (down 30.62% YoY), and the FY2025 full-year result was $43.3 million, down 43.72% from the prior year.
• Invested Capital for Q1 2026 stood at $53.9 million, up from $43.3 million in the prior quarter.
• The five-year high for Invested Capital was $85.3 million in Q1 2022, with the low at $22.0 million in Q3 2025.
• Historically, Invested Capital has averaged $65.3 million across 5 years, with a median of $69.2 million in 2023.
• Annual changes were most pronounced in 2024 — Invested Capital rose 24.17% — and 2025, when it plunged 65.98%.
• Lineage Cell Therapeutics' Invested Capital stood at $72.0 million in 2022, then dropped by 13.92% to $62.0 million in 2023, then climbed by 24.17% to $77.0 million in 2024, then tumbled by 43.72% to $43.3 million in 2025, then rose by 24.29% to $53.9 million in 2026.
• The last three Invested Capital figures came in at $53.9 million (Q1 2026), $43.3 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.